Abstract 365P
Background
Access to biopsy services is a limiting factor to timely lung cancer diagnosis in many areas in the Philippines. On-site pathology evaluation allows for rapid diagnosis and helps ensure adequate specimen sampling. In our institution, its utilization and impact have not yet been evaluated.
Methods
We reviewed biopsy records of patients diagnosed with lung cancer in a tertiary teaching hospital in the Philippines from September 2017 to August 2019. For each procedure, we determined whether on-site pathology evaluation was performed. Furthermore, its association with the need for re-biopsy, time to cancer diagnosis, receipt of systemic treatment and time to treatment initiation was determined. We used the z test for two proportions to anlayze binary variables, and the Mann-Whitney U test for continuous variables.
Results
A total of 112 pathology reports on 88 patients were reviewed. On-site evaluation was performed in 25 (22.3%) procedures (frozen section in 15, adequacy evaluation in 10). A re-biopsy was recommended in 37 procedures (33.0%) due to inadequate yield, of which only 24 (64.9%) were pursued. Patients who did not undergo on-site evaluation had a longer median time to cancer diagnosis (34 vs. 17 days, p = 0.04) and were more likely to require a re-biopsy (41% vs. 12%, p = 0.01). They were also less likely to eventually undergo systemic treatment (22.8% vs. 53.3%, p = 0.02), while a trend for a longer median time to treatment initiation did not reach statistical significance (145 vs. 83 days, p = 0.14). Among procedures where on-site evaluation was performed, there were only three instances when a repeat biopsy was recommended. In one case, the specimen was judged to be inadequate, but this was not followed by sampling of more tissue. In the other two cases, the specimen was deemed adequate but turned out to be insufficient for immunohistochemical evaluation.
Conclusions
On-site pathologic evaluation was associated with an earlier lung cancer diagnosis, a reduced need for a repeat biopsy, and a higher proportion of patients eventually receiving treatment. Efforts should be undertaken to increase the utilization of this service in order to optimize the quality of care for these patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
R.E. King: Research grant/Funding (institution), Recipient of Pfizer Global Medical Grant: Pfizer. All other authors have declared no conflicts of interest.
Resources from the same session
275P - Weekly paclitaxel, carboplatin and cetuximab (PCC) combination followed by nivolumab in platinum-sensitive recurrent and /or metastatic squamous cell carcinoma of head and neck: A double institution retrospective analysis from India
Presenter: Vivek Agarwala
Session: e-Poster Display Session
276P - Sarcopenia to predict overall survival in head and neck cancer patients receiving chemotherapy: A systematic review and meta-analysis
Presenter: Felix Kwenandar
Session: e-Poster Display Session
277P - Tegafur/uracil, platinum and cetuximab (UPEx) as first line treatment in frail patients with recurrent or metastatic head and neck squamous cell carcinoma
Presenter: Meng-che Hsieh
Session: e-Poster Display Session
278P - Serial assessment of parotid volume changes during radical chemoradiation of locally advanced head and neck cancer: Its implications in practice of adaptive radiotherapy
Presenter: Aathira T S
Session: e-Poster Display Session
279P - Clinico pathological characteristics and survival outcome in oral cavity cancer with masticator space involvement (T4b): A retrospective single institutional experience
Presenter: Abdulla Kunnummal Palathinkara
Session: e-Poster Display Session
280P - Safety and efficacy of concurrent chemoradiotherapy for head and neck cancers in younger versus older patients: Post hoc analysis of a randomized control trial
Presenter: Vanita Noronha
Session: e-Poster Display Session
281P - Prevalence of premalignant lesions and oral cancer among tobacco-using tea plantation workers of Nilgiri Hills, Tamilnadu, India
Presenter: Delfin Lovelina Francis
Session: e-Poster Display Session
282P - Filipino head and neck cancer patients and their quality of life
Presenter: Frederic Ivan Ting
Session: e-Poster Display Session
283P - Descriptive epidemiology of head and neck cancer in Niger: First results from the National Cancer Registry
Presenter: Salamatou Mamoudou Garba
Session: e-Poster Display Session
284P - Outcomes of metronomic adjuvant chemotherapy with tegafur-uracil in locally advanced head and neck squamous cell carcinoma
Presenter: Tsung-jang Yeh
Session: e-Poster Display Session